Loading...

Background

Why was GAFIO established

The global incidence of cancer continues to rise, both in high-income countries and, especially, in low- and middle-income countries. In 2020, there were approximately 19.3 million newly diagnosed cancer cases, and 10.0 million cancer-related deaths worldwide. By 2050, the number of cancer cases is predicted to increase 77% to 35 million cases. Meanwhile, the economic cost for cancer treatment and care has been escalating 6%-9% annually, standing at around US$550 billion as of 2020. Moreover, geographic and economic barriers result in significant disparities in cancer survival rates between high-, middle- and low-income countries, for instance 67% in the US, 50% in India, and as low as 30% in sub-Saharan Africa. The escalating cost and complexity of cancer treatment necessitate a radical transformation in cancer care.

19.3 M

diagnosed cancer

10.0 M

related deaths

550 B USD

economic cost

9.0 %

escalating annually

GAFIO offers three types

Membership Types

Professional Background: Individuals applying for membership should have a background or interest in oncology, informatics, artificial intelligence, or related fields.
Qualifications: Applicants may be required to hold a bachelor's degree or higher in a relevant field, such as medicine, informatics, engineering, or related disciplines.
Commitment to GAFIO’s Mission: Prospective members should support GAFIO's mission and goals, which often involve advancing oncology, AI, and patient care through education, research, and collaboration.
Relevant Experience: While not always mandatory, having professional experience or involvement in oncology or AI-related activities can strengthen an individual's application for membership.

Relevant Background:  Open to residents, fellows, and students enrolled in relevant undergraduate, graduate, doctoral, post-doctoral, or resident training programs.
Commitment to GAFIO’s Mission: Prospective members should support GAFIO's mission and goals, which often involve advancing oncology, AI, and patient care through education, research, and collaboration.

Organizational Profile: Corporate members are typically entities such as hospitals, medical institutions, research organizations, and companies involved in healthcare, oncology, AI, or related industries.
Commitment to GAFIO's Mission: Similar to individual members, corporate members should align with GAFIO's mission and goals, especially in areas related to oncology, AI, and healthcare innovation.
Legal Entity Status: Corporate members must have legal entity qualifications or represent social groups with an interest in oncology, AI, or related social welfare activities.
Financial Commitment: Corporate members may be required to pay membership dues or fees based on their organizational size or membership tier.

Latest News

8/29/2026
Journal Paper Roundup — AI and Lung Cancer

Intelligent Oncology continues to deliver high-impact research in lung cancer, spanning radiomics to clinical decision-making.

Read More
8/23/2026
From Cells to Patients: Multiscale Computational Pathology in the Era of Foundation Models and Vision-Language Systems

In this comprehensive review, the authors critically evaluate the transformative impact of foundation models and vision-language systems on computational pathology, framing their analysis through a multiscale lens—from cellular morphology and tissue microenvironments to whole-slide image (WSI) analysis and patient-level multimodal integration. Moving beyond traditional task-specific deep learning solutions, the review examines how these emerging data-driven systems are redefining pathological analysis across diverse spatial scales and bridging the gap between pixel-level features and patient-centric clinical decision-making.

Read More
8/19/2026
Artificial intelligence in robot-assisted radical prostatectomy — From technical innovation to clinical translation

In this comprehensive review, the authors critically evaluate the current state and clinical translational potential of AI in robot-assisted radical prostatectomy (RARP). Moving beyond technical novelty, the authors examine whether AI can meaningfully improve surgical outcomes in one of the most common urologic oncologic procedures.

Read More

Becoming a member

If you have a common vision with us, join us

Image

Please fill out the form

Fill in this information to help us understand you and create a private profile for you.

Email available
Email unavailable
Get
Verification code required
Password required
Confirm password required
Please select country or region
Please select member type
First Name required
Last/Family Name required
Please select gender
Please select Academic Degree
Affiliation required
Major Focus required
Cancer Subspecialties required